Related references
Note: Only part of the references are listed.Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
Jill J. Bastman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Inigo Lancia et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAFV600E Mutation-Prevalent Area
Min Ji Jeon et al.
THYROID (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
John W. Kunstman et al.
HUMAN MOLECULAR GENETICS (2015)
Immune Checkpoint Blockade in Cancer Therapy The 2015 Lasker-DeBakey Clinical Medical Research Award
James P. Allison
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
Jill J. Severson et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience
A. Mohebati et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration
Trevor E. Angell et al.
THYROID (2014)
Multimodality therapeutic outcomes In anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors
Ken-ichi Ito et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients
Iwao Sugitani et al.
WORLD JOURNAL OF SURGERY (2012)
Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review
Eric J. Sherman et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy
Robert L. Foote et al.
THYROID (2011)
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2008)
Anaplastic thyroid cancer in British Columbia 1985-1999: A population-based study
V Goutsouliak et al.
CLINICAL ONCOLOGY (2005)
Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy
R De Crevoisier et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Anaplastic thyroid carcinoma: A 50-year experience at a single institution
B McIver et al.
SURGERY (2001)
Share Paper
